Next Article in Journal / Special Issue
Edwardsiella tarda OmpA Encapsulated in Chitosan Nanoparticles Shows Superior Protection over Inactivated Whole Cell Vaccine in Orally Vaccinated Fringed-Lipped Peninsula Carp (Labeo fimbriatus)
Previous Article in Journal
Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer
Previous Article in Special Issue
Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting
Article Menu

Export Article

Open AccessReview
Vaccines 2016, 4(4), 39;

Replicon RNA Viral Vectors as Vaccines

PanTherapeutics, CH 1095 Lutry, Switzerland
Academic Editor: Olga Borges
Received: 13 July 2016 / Revised: 14 October 2016 / Accepted: 28 October 2016 / Published: 7 November 2016
(This article belongs to the Special Issue Nanoparticles to Co-Deliver Immunopotentiators and Antigens)
Full-Text   |   PDF [2203 KB, uploaded 7 November 2016]   |  


Single-stranded RNA viruses of both positive and negative polarity have been used as vectors for vaccine development. In this context, alphaviruses, flaviviruses, measles virus and rhabdoviruses have been engineered for expression of surface protein genes and antigens. Administration of replicon RNA vectors has resulted in strong immune responses and generation of neutralizing antibodies in various animal models. Immunization of mice, chicken, pigs and primates with virus-like particles, naked RNA or layered DNA/RNA plasmids has provided protection against challenges with lethal doses of infectious agents and administered tumor cells. Both prophylactic and therapeutic efficacy has been achieved in cancer immunotherapy. Moreover, recombinant particles and replicon RNAs have been encapsulated by liposomes to improve delivery and targeting. Replicon RNA vectors have also been subjected to clinical trials. Overall, immunization with self-replicating RNA viruses provides high transient expression levels of antigens resulting in generation of neutralizing antibody responses and protection against lethal challenges under safe conditions. View Full-Text
Keywords: alphaviruses; flaviviruses; measles viruses; rhabdoviruses; antibodies; infectious diseases; tumors; disease protection alphaviruses; flaviviruses; measles viruses; rhabdoviruses; antibodies; infectious diseases; tumors; disease protection

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Lundstrom, K. Replicon RNA Viral Vectors as Vaccines. Vaccines 2016, 4, 39.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top